Quest Diagnostics highlights long-term strategy, shares hold near recent highs
27.06.2026 - 10:39:40 | ad-hoc-news.de
By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-27, 10:39.
Quest Diagnostics (US74834L1008) continues to build out its diagnostics and health information services platform as a major US laboratory operator on the NASDAQ. The focus for investors is the company’s long-term strategy in diagnostic testing and data as shares trade around 210 dollars according to recent market data.
How Quest Diagnostics positions itself
Quest Diagnostics is widely known as a national provider of diagnostic information services in the United States, operating a broad network of laboratories and patient service centers across the country as described in its corporate materials.Company overview on the Quest Diagnostics site The company’s core strategic ambition is to help physicians, hospitals, insurers and patients improve decision-making with accurate lab results and related information.
In recent years Quest Diagnostics has emphasized a combination of organic growth and targeted acquisitions to expand its testing menu and geographic reach, particularly in specialized diagnostics such as oncology, cardiometabolic risk assessment and infectious disease testing according to its investor materials.Quest Diagnostics investor information The company positions itself against other US healthcare providers and services groups, including sector peers such as Labcorp, by highlighting scale, data capabilities and payer relationships.
Valuation metrics and sector context
Quest Diagnostics shares trade under the ticker DGX on the NYSE, and recent data from valuation platforms show the stock with a price to earnings ratio in the low-20s, indicating a moderate valuation relative to the broader Healthcare Providers & Services industry.TradingKey valuation snapshot for Quest Diagnostics One analysis reports a P/E ratio around 22.8, with the company ranked in the upper half of its sector by a composite valuation score.
Separate price data sources show that Quest Diagnostics shares recently traded near 209 to 210 dollars, with an intraday high close to 209.9 dollars on June 26 and volume of roughly 1.35 million shares, pointing to a liquid listing for a mid- to large-cap healthcare name.Recent DGX price and volume data This level places the stock not far from analyst consensus price indications, suggesting neither extreme discount nor marked premium based on the cited forecast source.
All news and data on the Quest Diagnostics shares
Further articles and price information on Quest Diagnostics can be found in the dedicated topic section and on the company’s investor relations pages.
The diagnostics business behind the stock
Quest Diagnostics generates most of its revenue by performing clinical laboratory tests for physicians, hospitals, health systems, employers and government programs, with a broad test menu ranging from routine blood work and chemistry panels to advanced molecular diagnostics according to its corporate description.Quest Diagnostics testing services overview The company also offers wellness screening programs, employer-focused health solutions and data analytics services that use aggregated laboratory information to support population health initiatives.
Where the shares trade today
The Quest Diagnostics shares (US74834L1008) most recently traded around 209.9 US dollars on the NYSE in the session dated 2026-06-26, based on publicly available quote data. This price level as of 2026-06-26, 21:00 places the equity close to its recent trading range near the 210 dollar mark.
Key data on the Quest Diagnostics shares
- Company: Quest Diagnostics Inc.
- ISIN: US74834L1008
- WKN: 918895
- Ticker: DGX
- Trading venue: NYSE
- Price (as of 2026-06-26, 21:00): 209.9 USD
- Market cap: approximately 23 billion USD (as of 2026-06-26)
- Sector / industry: Healthcare Providers & Services / Diagnostics
- Index membership: S&P 500
- Next earnings date: not officially scheduled
Disclaimer: This article is for informational purposes only and does not contain investment advice, buy or sell recommendations, or price targets. All data and assessments are based on publicly available sources believed to be reliable at the time of review, but their accuracy and completeness cannot be guaranteed.
